Answers are grounded in this paper and cite their sources.
Background Cancer patients on immune checkpoint inhibitors (ICIs) can rarely develop concurrent myocarditis, myositis, and myasthenia gravis, known as 3M syndrome. While a few reviews have been published to better understand the characteristics of 3M patients, no study to date has identified predictors of mortality in these patients.Methods We systematically reviewed five databases for published cases of 3M syndrome from 2014 to 2024. Of 113 articles, we identified 153 adult 3M patients. For each patient, we recorded demographic data, ICI regimen, symptoms, diagnostic findings, treatment modalities, and discharge outcomes. Using multivariable logistic regression, we compared variables by mortality.Results Patients had a median age of 72 years, were predominantly male (73%), and were diagnosed with melanoma (32%). Pembrolizumab (30%) was the most common ICI. Common symptoms were dyspnea (59%), muscle weakness (59%), and dysphagia (37%), and most (73%) had varying degree ocular involvement. Troponin and creatinine kinase were elevated in nearly all patients. We identified three characteristics related to mortality: older age (P = 0.005), elevated liver enzymes (P = 0.02), and intubation (P = 0.002). We also identified factors related to survival: treatment with rituximab (P = 0.04) or abatacept (P = 0.02), elevated lactate dehydrogenase (P = 0.03), and tracheostomy (P = 0.046).Conclusion Further investigation into potential predictors of survival in 3M syndrome patients, particularly regarding rituximab and abatacept use, may improve patient care and outcomes.
No takes yet. Share an insight, caveat, or question.
Kolluri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: